The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...

Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.

Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just ...

In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune ...

McKinsey fined $650M for helping boost OxyContin sales, misleading FDA about conflicts. Ex-partner Martin Elling charged with ...

Bicycle Therapeutics reports mixed data for zelenectide pevedotin in cancer trials, with 60% response rate in urothelial ...

San Antonio Breast Cancer Conference featured updates on VEGF bispecifics, oral protein degraders, and data from BeiGene, ...

The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in ...

BeiGene acquires MTAP deletion drug SYH2039 from CSPC for $150M, plans combo with BGB-58067, competing with Ideaya's IDE397 ...

Teos Therapeutics halts inupadenant development after poor Phase 2 NSCLC data, and shifts focus to TIGIT program, a combo of ...